Long-Acting Lipoglycopeptides for Skin and Soft Tissue Infections : Implementation Into Practice
Hear Kyle Molina, PharmD, BCIDP, discuss key considerations to ensure successful implementation of long-acting lipoglycopeptides for ABSSSI treatment into practice, such as justifying cost, targeting the right patient population, selecting between infusion locations, and maximizing institutional impact.
Decera Clinical Education Infectious Disease Podcast · Kyle Molina PharmD BCIDP
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Kyle Molina, PharmD, BCIDP, discusses key considerations for successful implementation of long-acting lipoglycopeptides into clinical practice. Listen as he gives perspectives on:
- Reasons to consider use of long-acting lipoglycopeptides (eg, poor adherence to oral antibiotics, PICC-related costs and complications)
- Data supporting and challenging cost effectiveness of long-acting lipoglycopeptides
- Identifying the target patient population
- Selecting the right location to provide long-acting lipoglycopeptides
- Strategies to maximize institutional impact with key stakeholders (eg, hospital avoidance, reduced ED and hospital length of stay)
- Key characteristics of available long-acting lipoglycopeptides
- Addressing logistical challenges, including navigating the reimbursement process
Faculty:
Kyle Molina, PharmD, BCIDP
Infectious Diseases Clinical Pharmacist
Scripps Green Hospital
La Jolla, California
Link to full program:
- CCO: https://bit.ly/3J4mg8h
- ProCE: https://bit.ly/3P0vB4E
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.